Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
12 studies found for:    "Acral lentiginous melanoma"
Show Display Options
RSS Create an RSS feed from your search for:
"Acral lentiginous melanoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma
Condition: Acral Lentiginous Melanoma
Intervention: Drug: pembrolizumab
2 Not yet recruiting A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Conditions: Acral Lentiginous Melanoma;   Mucosal Melanoma
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
3 Unknown  A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Conditions: Mucosal Lentiginous Melanoma;   Acral Lentiginous Malignant Melanoma
Intervention: Drug: nilotinib
4 Active, not recruiting SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Conditions: Mucosal Lentiginous Melanoma;   Acral Lentiginous Malignant Melanoma
Intervention: Drug: Sunitinib
5 Active, not recruiting
Has Results
Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Melanoma;   Lentigo Maligna Melanoma;   Mucosal Melanoma;   Nodular Melanoma;   Recurrent Melanoma;   Stage IV Skin Melanoma;   Superficial Spreading Melanoma
Intervention: Drug: Dinaciclib
6 Completed
Has Results
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Conditions: Acral Lentiginous Malignant Melanoma;   Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: imatinib mesylate;   Other: laboratory biomarker analysis
7 Terminated
Has Results
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Solar Radiation-related Skin Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
8 Completed
Has Results
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Intraocular Melanoma;   Iris Melanoma;   Lentigo Maligna Malignant Melanoma;   Recurrent Melanoma;   Stage, Intraocular Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: cediranib maleate
9 Terminated
Has Results
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
Condition: Melanoma
Interventions: Drug: Dasatinib;   Procedure: Surgical Resection
10 Completed Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: adenovirus RSV-TK;   Drug: ganciclovir
11 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
12 Recruiting Study of Families With Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: examination;   Procedure: mutation carrier screening;   Procedure: study of high risk factors

Study has passed its completion date and status has not been verified in more than two years.